Continuous Venovenous Hemodiafiltration Versus Sustained Low-efficiency Hemodialysis for Critically Ill Patients With Acute Kidney Injury in Intensive Care Unit

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02879201

Enrollment

Registered

2016-08-25

Start date

2009-01-31

Completion date

2016-06-30

Last updated

2023-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Injury

Brief summary

The investigators conducted a comparison trial between SLED and CRRT in critically ill patients to evaluate the outcome for all cause mortality at 30 day . The secondary outcome were recovery of renal function, complications during therapy and duration of hospitalization.

Detailed description

The investigators performed a single center experience accumulated over 12 months since February 2009 with a continuous venovenous hemodiafiltration (CVVHDF) and hybrid technique named sustained low-efficiency dialysis (SLED). The primary end point was death from any cause by day 30. Intensive care unit (ICU) patients were eligible for inclusion when serum creatinine was \> 2 mg/dL, and renal replacement therapy (RRT) was initiated. The selected patients were treated with CVVHDF or SLED.

Interventions

PROCEDURESlow efficiency dialysis

Slow dialysis 4 times weekly 8 hours CVVHDF predilution mode

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Inclusion criteria

\- The inclusion criteria were 1. AKI requiring RRT 2. Hemodynamic instability defined by systolic blood pressure ≤ 90 mmHg and/or diastolic blood pressure ≤ 60 mmHg 3. Patients requiring initiation to vasopressor support

Exclusion criteria

* Patients with pre-existing chronic kidney disease ( eGFR less than 30 mLmin/1.73m2) were excluded

Design outcomes

Primary

Measure	Time frame	Description
All-cause mortality	30 day	ll-cause mortality at 30 days following RRT initiation

Secondary

Measure	Time frame	Description
Numbers of patients with abnormal laboratory values	30 days	Renal function impairment
ICU stay	30 days	Total days in ICU

Other

Measure	Time frame	Description
Adverse events during treatment	30 days	Number of patients with catheter infection

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026